Zafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced that Thomas Hughes, Ph.D., president and chief executive officer, will be presenting at the BioCentury 18th Annual Future Leaders in the Biotech Industry Conference, being held Friday, April 15 at the Millennium Broadway Hotel & Conference Center in New York City. Dr. Hughes will present a company overview at 10:30 a.m. in presentation room 508.

About Zafgen, Inc.

Zafgen is pioneering novel obesity therapeutics that directly target fat metabolism to help the body regain and sustain a lean, healthy state. The company’s approach focuses on restoring control of key metabolic processes, releasing stored fat which then is used by the body as fuel. Zafgen’s first generation product, named ZGN-433, is being studied in a Phase 1b clinical trial for its use as a pharmacological alternative to bariatric surgery in the treatment of severe obesity. Zafgen's leadership and scientific advisors include leading experts in obesity, metabolic disorders and medicinal chemistry. Founded in 2005, the company is located in Cambridge, Mass. For more information, visit www.zafgen.com.



CONTACT:

Pure Communications, Inc.
Michele Rozen, 617-730-8284

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.